The Scottish Early Rheumatoid Arthritis (SERA) Study

an inception cohort and biobank

James Dale (Lead / Corresponding author), Caron Paterson, Ann Tierney, Stuart H. Ralston, David M. Reid, Neil Basu, John Harvie, Neil D. McKay, Sarah Saunders, Hilary Wilson, Robin Munro, Ruth Richmond, Derek Baxter, Michael McMahon, John McLaren, Vinod Kumar, Stefan Siebert, Iain McInnes, Duncan Porter

    Research output: Contribution to journalArticle

    5 Citations (Scopus)
    84 Downloads (Pure)

    Abstract

    Background: The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate discovery of phenotypic and prognostic biomarkers.

    Methods: Demographic and clinical outcome data are collected from newly diagnosed RA/UA patients every 6 months from around Scotland. Health service utilization data is acquired from Information Services Division, NHS National Services Scotland. Plain radiographs of hands and feet are collected at baseline and 12 months. Additional samples of whole blood, plasma, serum and filtered urine are collected at baseline, 6 and 12 months.

    Results: Results are available for 1073 patients; at baseline, 76 % were classified as RA and 24 % as UA. Median time from onset to first review was 163 days (IQR97-323). Methotrexate was first-line DMARD for 75 % patients. Disease activity, functional ability and health-related quality of life improved significantly between baseline and 24 months, however the proportion in any employment fell (51 to 38 %, p = 0.0005). 24 % patients reported symptoms of anxiety and/or depression at baseline. 35/391 (9 %) patients exhibited rapid radiographic progression after 12 months. The SERA Biobank has accrued 60,612 samples.

    Conclusions: In routine care, newly diagnosed RA/UA patients experience significant improvements in disease activity, functional ability and health-related quality of life but have high rates of psychiatric symptoms and declining employment rates. The co-existence of a multi-domain description of phenotype and a comprehensive biobank will facilitate multi-platform translational research to identify predictive markers of phenotype and prognosis.

    Original languageEnglish
    Article number461
    Pages (from-to)1-8
    Number of pages8
    JournalBMC Musculoskeletal Disorders
    Volume17
    DOIs
    Publication statusPublished - 9 Nov 2016

    Fingerprint

    Rheumatoid Arthritis
    Cohort Studies
    Aptitude
    Scotland
    Phenotype
    Quality of Life
    Antirheumatic Agents
    Translational Medical Research
    Information Services
    Methotrexate
    Health Services
    Arthritis
    Psychiatry
    Foot
    Anxiety
    Hand
    Biomarkers
    Demography
    Urine
    Depression

    Cite this

    Dale, J., Paterson, C., Tierney, A., Ralston, S. H., Reid, D. M., Basu, N., ... Porter, D. (2016). The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. BMC Musculoskeletal Disorders, 17, 1-8. [461]. https://doi.org/10.1186/s12891-016-1318-y
    Dale, James ; Paterson, Caron ; Tierney, Ann ; Ralston, Stuart H. ; Reid, David M. ; Basu, Neil ; Harvie, John ; McKay, Neil D. ; Saunders, Sarah ; Wilson, Hilary ; Munro, Robin ; Richmond, Ruth ; Baxter, Derek ; McMahon, Michael ; McLaren, John ; Kumar, Vinod ; Siebert, Stefan ; McInnes, Iain ; Porter, Duncan. / The Scottish Early Rheumatoid Arthritis (SERA) Study : an inception cohort and biobank. In: BMC Musculoskeletal Disorders. 2016 ; Vol. 17. pp. 1-8.
    @article{4435484eba184d18b627c3e9fd2f567c,
    title = "The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank",
    abstract = "Background: The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate discovery of phenotypic and prognostic biomarkers.Methods: Demographic and clinical outcome data are collected from newly diagnosed RA/UA patients every 6 months from around Scotland. Health service utilization data is acquired from Information Services Division, NHS National Services Scotland. Plain radiographs of hands and feet are collected at baseline and 12 months. Additional samples of whole blood, plasma, serum and filtered urine are collected at baseline, 6 and 12 months.Results: Results are available for 1073 patients; at baseline, 76 {\%} were classified as RA and 24 {\%} as UA. Median time from onset to first review was 163 days (IQR97-323). Methotrexate was first-line DMARD for 75 {\%} patients. Disease activity, functional ability and health-related quality of life improved significantly between baseline and 24 months, however the proportion in any employment fell (51 to 38 {\%}, p = 0.0005). 24 {\%} patients reported symptoms of anxiety and/or depression at baseline. 35/391 (9 {\%}) patients exhibited rapid radiographic progression after 12 months. The SERA Biobank has accrued 60,612 samples.Conclusions: In routine care, newly diagnosed RA/UA patients experience significant improvements in disease activity, functional ability and health-related quality of life but have high rates of psychiatric symptoms and declining employment rates. The co-existence of a multi-domain description of phenotype and a comprehensive biobank will facilitate multi-platform translational research to identify predictive markers of phenotype and prognosis.",
    author = "James Dale and Caron Paterson and Ann Tierney and Ralston, {Stuart H.} and Reid, {David M.} and Neil Basu and John Harvie and McKay, {Neil D.} and Sarah Saunders and Hilary Wilson and Robin Munro and Ruth Richmond and Derek Baxter and Michael McMahon and John McLaren and Vinod Kumar and Stefan Siebert and Iain McInnes and Duncan Porter",
    note = "The SERA study was jointly supported by the Chief Scientist’s Office Scotland (ETM-40) and Pfizer Ltd.",
    year = "2016",
    month = "11",
    day = "9",
    doi = "10.1186/s12891-016-1318-y",
    language = "English",
    volume = "17",
    pages = "1--8",
    journal = "BMC Musculoskeletal Disorders",
    issn = "1471-2474",
    publisher = "Springer Verlag",

    }

    Dale, J, Paterson, C, Tierney, A, Ralston, SH, Reid, DM, Basu, N, Harvie, J, McKay, ND, Saunders, S, Wilson, H, Munro, R, Richmond, R, Baxter, D, McMahon, M, McLaren, J, Kumar, V, Siebert, S, McInnes, I & Porter, D 2016, 'The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank', BMC Musculoskeletal Disorders, vol. 17, 461, pp. 1-8. https://doi.org/10.1186/s12891-016-1318-y

    The Scottish Early Rheumatoid Arthritis (SERA) Study : an inception cohort and biobank. / Dale, James (Lead / Corresponding author); Paterson, Caron; Tierney, Ann; Ralston, Stuart H.; Reid, David M.; Basu, Neil; Harvie, John; McKay, Neil D.; Saunders, Sarah; Wilson, Hilary; Munro, Robin; Richmond, Ruth; Baxter, Derek; McMahon, Michael; McLaren, John; Kumar, Vinod; Siebert, Stefan; McInnes, Iain; Porter, Duncan.

    In: BMC Musculoskeletal Disorders, Vol. 17, 461, 09.11.2016, p. 1-8.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - The Scottish Early Rheumatoid Arthritis (SERA) Study

    T2 - an inception cohort and biobank

    AU - Dale, James

    AU - Paterson, Caron

    AU - Tierney, Ann

    AU - Ralston, Stuart H.

    AU - Reid, David M.

    AU - Basu, Neil

    AU - Harvie, John

    AU - McKay, Neil D.

    AU - Saunders, Sarah

    AU - Wilson, Hilary

    AU - Munro, Robin

    AU - Richmond, Ruth

    AU - Baxter, Derek

    AU - McMahon, Michael

    AU - McLaren, John

    AU - Kumar, Vinod

    AU - Siebert, Stefan

    AU - McInnes, Iain

    AU - Porter, Duncan

    N1 - The SERA study was jointly supported by the Chief Scientist’s Office Scotland (ETM-40) and Pfizer Ltd.

    PY - 2016/11/9

    Y1 - 2016/11/9

    N2 - Background: The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate discovery of phenotypic and prognostic biomarkers.Methods: Demographic and clinical outcome data are collected from newly diagnosed RA/UA patients every 6 months from around Scotland. Health service utilization data is acquired from Information Services Division, NHS National Services Scotland. Plain radiographs of hands and feet are collected at baseline and 12 months. Additional samples of whole blood, plasma, serum and filtered urine are collected at baseline, 6 and 12 months.Results: Results are available for 1073 patients; at baseline, 76 % were classified as RA and 24 % as UA. Median time from onset to first review was 163 days (IQR97-323). Methotrexate was first-line DMARD for 75 % patients. Disease activity, functional ability and health-related quality of life improved significantly between baseline and 24 months, however the proportion in any employment fell (51 to 38 %, p = 0.0005). 24 % patients reported symptoms of anxiety and/or depression at baseline. 35/391 (9 %) patients exhibited rapid radiographic progression after 12 months. The SERA Biobank has accrued 60,612 samples.Conclusions: In routine care, newly diagnosed RA/UA patients experience significant improvements in disease activity, functional ability and health-related quality of life but have high rates of psychiatric symptoms and declining employment rates. The co-existence of a multi-domain description of phenotype and a comprehensive biobank will facilitate multi-platform translational research to identify predictive markers of phenotype and prognosis.

    AB - Background: The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate discovery of phenotypic and prognostic biomarkers.Methods: Demographic and clinical outcome data are collected from newly diagnosed RA/UA patients every 6 months from around Scotland. Health service utilization data is acquired from Information Services Division, NHS National Services Scotland. Plain radiographs of hands and feet are collected at baseline and 12 months. Additional samples of whole blood, plasma, serum and filtered urine are collected at baseline, 6 and 12 months.Results: Results are available for 1073 patients; at baseline, 76 % were classified as RA and 24 % as UA. Median time from onset to first review was 163 days (IQR97-323). Methotrexate was first-line DMARD for 75 % patients. Disease activity, functional ability and health-related quality of life improved significantly between baseline and 24 months, however the proportion in any employment fell (51 to 38 %, p = 0.0005). 24 % patients reported symptoms of anxiety and/or depression at baseline. 35/391 (9 %) patients exhibited rapid radiographic progression after 12 months. The SERA Biobank has accrued 60,612 samples.Conclusions: In routine care, newly diagnosed RA/UA patients experience significant improvements in disease activity, functional ability and health-related quality of life but have high rates of psychiatric symptoms and declining employment rates. The co-existence of a multi-domain description of phenotype and a comprehensive biobank will facilitate multi-platform translational research to identify predictive markers of phenotype and prognosis.

    U2 - 10.1186/s12891-016-1318-y

    DO - 10.1186/s12891-016-1318-y

    M3 - Article

    VL - 17

    SP - 1

    EP - 8

    JO - BMC Musculoskeletal Disorders

    JF - BMC Musculoskeletal Disorders

    SN - 1471-2474

    M1 - 461

    ER -